Topics:
Rheumatology • Vasculitis • ANCA Vasculitis • Journal Club ft. NEJM publications • Dermatology
Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but wondering if there are any trends/signals.
Answer from: at Community Practice
The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...
Sign in or Register to read more